Journal Article

Clinical course of 63 patients with neonatal onset urea cycle disorders in the years 2001–2013

Konstantopoulou, Vassiliki, Mayorandan, Sebene, Thimm, Eva, Häberle, Johannes, de Lonlay, Pascale, Derbinski, Jens, Hoffmann, Georg F., Unsinn, Caroline, Beblo, Skadi, Das, Anibh, Rennecke, Jörg, Valayannopoulos, Vassili, Burlina, Alberto

2016

Overview

Background Urea cycle disorders (UCDs) are rare inherited metabolic defects of ammonia detoxification. In about half of patients presenting with a UCD, the first symptoms appear within a few days after birth. These neonatal onset patients generally have a severe defect of urea cycle function and their survival and outcome prognoses are often limited. To understand better the current situation of neonatal onset in UCDs, we have performed a multicentre, retrospective, non-interventional case series study focussing on the most severe UCDs, namely defects of carbamoyl phosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), and argininosuccinate synthetase (ASS). Methods and results Data of 63 patients were collected (27 patients with ASS deficiency, 23 patients with OTC deficiency, and 12 patients with CPS1 deficiency, one patient definite diagnosis not documented). The majority of patients (43/63, 68 %) had an initial ammonia concentration exceeding 500 μmol/L (normal < 100), of which most (26/43, 60.5 %) were also encephalopathic and were treated with hemodialysis. In patients surviving the initial crisis, recurrence of hyperammonemic events within the first 1.5 years of life occurred frequently (mean 3.6 events, range 0–20). Of all patients, 16 (25.4 %) died during or immediately after the neonatal period. Conclusion We observed in this cohort of neonatal onset UCD patients a high rate of initial life-threatening hyperammonemia and a high risk of recurrence of severe hyperammonemic crises. These corresponded to a high mortality rate during the entire study period (30.2 %) despite the fact that patients were treated in leading European metabolic centers. This underlines the need to critically re-evaluate the current treatment strategies in these patients.

• Publisher: BioMed Central,BioMed Central Ltd
• Subject: Analysis / Arginine - therapeutic use / Child, Preschool / Female / Health aspects / Human Genetics / Humans / Hyperammonemia / Hyperammonemia - drug therapy / Hyperammonemia - mortality / Hyperammonemia - pathology / Hyperammonemia - surgery / Infant / Infants (Newborn) / Inherited metabolic diseases / Kaplan-Meier Estimate / Liver Transplantation / Male / Medicine / Medicine & Public Health / Ornithine Carbamoyltransferase Deficiency Disease - drug therapy / Ornithine Carbamoyltransferase Deficiency Disease - mortality / Ornithine Carbamoyltransferase Deficiency Disease - pathology / Ornithine Carbamoyltransferase Deficiency Disease - surgery / Pharmacology/Toxicology / Prognosis / Retrospective Studies / Sodium Benzoate - therapeutic use / Urea cycle / Urea Cycle Disorders, Inborn - drug therapy / Urea Cycle Disorders, Inborn - mortality / Urea Cycle Disorders, Inborn - pathology / Urea Cycle Disorders, Inborn - surgery